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Abstract Antigen uptake by dendritic cells and intracellular routing of antigens to specific
compartments is regulated by C-type lectin receptors that recognize glycan structures. We show
that the modification of Ovalbumin (OVA) with the glycan-structure LewisX (LeX) re-directs OVA to
the C-type lectin receptor MGL1. LeX-modification of OVA favored Th1 skewing of CD4+ T cells
and enhanced cross-priming of CD8+ T cells. While cross-presentation of native OVA requires high
antigen dose and TLR stimuli, LeX modification reduces the required amount 100-fold and obviates
its dependence on TLR signaling. The OVA-LeX-induced enhancement of T cell cross-priming is
MGL1-dependent as shown by reduced CD8+ effector T cell frequencies in MGL1-deficient mice.
Moreover, MGL1-mediated cross-presentation of OVA-LeX neither required TAP-transporters nor
Cathepsin-S and was still observed after prolonged intracellular storage of antigen in
Rab11+LAMP1+ compartments. We conclude that controlled neo-glycosylation of antigens can
crucially influence intracellular routing of antigens, the nature and strength of immune responses
and should be considered for optimizing current vaccination strategies.
DOI: 10.7554/eLife.11765.001
Introduction
The induction of T cell immunity to viruses or tumors involves the presentation of viral or tumor anti-
gens by antigen-presenting cells (APC) in the context of major histocompatibility complex (MHC)
molecules. Loading of exogenously-derived antigens onto MHC class I molecules, a process known
as cross-presentation (Carbone and Bevan, 1990) is required to activate antigen-specific CD8+ T
cells. Furthermore, cognate CD4+ T cell help is important for licensing the APC, which is essential
for effective CD8+ T cell priming and induction of long-lasting memory (Bennett et al., 1997;
Schoenberger et al., 1998). The molecular mechanisms underlying cross-presentation have been
studied intensively, however, little is still known on the nature of the antigens and stimuli that are
required for APC to route exogenous antigens efficiently into the MHC class I presentation pathway.
Most exogenous antigens that originate from tumor cells or viruses are glycosylated in their
native form (Apweiler et al., 1999). The relative composition of the glycosylation machinery, which
includes all the necessary glycosylation-related enzymes and co-factors, determines the final configu-
ration of the glycan structures that decorate N- or O-linked glycosylation sites present in glycopro-
teins. The glycosylation machinery can be affected by multiple physio-pathological cues, including
proliferation, activation, and the transformation status of the cell (Ohtsubo and Marth, 2006), and
depends on environmental factors. APC, such as dendritic cells (DCs) and macrophages are able to
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sense glycans exposed on either self- or pathogen-derived antigens via glycan-binding proteins.
Amongst these glycan-binding proteins are C-type lectin receptors (CLRs) that recognize defined
carbohydrate-structures through their carbohydrate recognition domain (CRD). Depending on the
amino acid sequence, the CRD bears specificity for mannose, fucose, galactose, sialylated-, or sul-
fated structures. CLRs function both as antigen uptake and/or signaling receptors that modify DC-
induced cytokine responses thereby influencing T cell differentiation (van and Rabinovich, 2008).
The specialized internalization motifs in the cytoplasmic domains of CLRs allow the rapid internaliza-
tion of antigens upon interaction (Engering et al., 2002; Herre et al., 2004). This suggests that DCs
use CLRs to ’sense’ the natural glycan composition of tissues and invading pathogens and, in
response to this recognition, are able to modulate immune responses (Geijtenbeek and Gringhuis,
2009).
The conjugation of antigens to CLRs-specific antibodies, such as DEC205, mannose receptor
(MR), Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) or
CLEC9A, has proven to be an effective way to direct antigens to DCs, resulting in enhanced antigen
uptake and presentation on MHC molecules (Bonifaz et al., 2004; Hawiger et al., 2001;
Caminschi et al., 2008; Chatterjee et al., 2012). Also glycans specific for CLRs have shown their tar-
geting specificity and potential to improve antigen uptake and presentation in MHC class I and II
molecules when coupled to antigen formulations (Singh et al., 2009a; Garcia-Vallejo et al., 2013;
Unger et al., 2012; Unger, 2014; Aarnoudse et al., 2008; Yang et al., 2008; Singh et al., 2011).
To achieve immunity rather than tolerance inclusion of a strong adjuvant is necessary. Little is known
on how naturally glycosylated antigens or alterations in the glycosylation of antigens may change
and re-direct antigen internalization via CLRs, in addition to subsequent processing and
presentation.
MR was shown to mediate cross-presentation of the model-antigen ovalbumin (OVA) in a Toll-like
receptor (TLR)-dependent manner and to recruit TAP-1 to endocytic organelles (Burgdorf et al.,
eLife digest Immune cells called dendritic cells play a crucial role in defending the body against
tumor cells and invading viruses. The dendritic cells take up molecules called antigens from these
threats and then display them on their surface. This enables the antigens to be identified by other
immune cells that are capable of killing the viruses and the tumor cells. The dendritic cells recognize
the antigens with the help of receptor proteins called C-type lectin receptors (CLRs). These
receptors can bind to sugar molecules that are naturally found on many antigens. For example, a C-
type lectin receptor called MGL1 can bind to sugars known as LewisX and Lewisa on tumor and virus
proteins. However, it is not clear how important these receptors are in triggering immune
responses.
An antigen called Ovalbumin – which is found in chicken egg white – can trigger immune
responses in mammals and so researchers often use it to study the immune system. Although this
antigen has several sugar molecules attached to it, quite a large amount of Ovalbumin is needed to
trigger strong immune responses. Now, Streng-Ouwehand et al. examine whether attaching LewisX
to Ovalbumin can results in stronger immune responses in mice.
The experiments show that injecting mice with Ovalbumin-LewisX triggers a much stronger
immune response than normal Ovalbumin does. This enhanced response was not observed in mice
that lacked the MGL1 receptor, which suggests that this receptor is involved in detecting
Ovalbumin-LewisX. Furthermore, the dendritic cells store the altered Ovalbumin for longer than they
store normal Ovalbumin, which gives the cells more time to present the altered Ovalbumin to other
immune cells.
Vaccines and some other therapies help to boost immune responses to viruses and tumors by
exposing the body to antigens. However, these therapies often use antigens that don’t have sugar
molecules attached to them, or are missing the sugar molecules they would normally have. Streng-
Ouwehand et al.’s findings suggest that adding specific sugars to antigens in immune therapies
might help to make these therapies more effective.
DOI: 10.7554/eLife.11765.002
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2007; Burgdorf et al., 2008). Importantly, cross-presentation of OVA was only effective using high
amounts of antigen (Burgdorf et al., 2007; Burgdorf et al., 2008). The interaction of OVA with MR,
which has specificity for mannose (Taylor et al., 1992), was speculated to be dependent on the
presence of mannose glycans on OVA (Burgdorf et al., 2007). In the current study, we investigated
the effect of modifying the glycan composition of OVA on the efficacy of cross-presentation, priming
and differentiation of T cells. We hypothesized that modification of the antigen with specific glycans
would re-direct antigens to other CLRs resulting in altered intracellular routing and presentation of
antigen and Th differentiation. We have chosen to conjugate the carbohydrate structure LewisX (LeX)
to 2 free cysteine residues within the native OVA glycoprotein. LeX is a ligand of the murine C-type
lectin macrophage galactose-type lectin (MGL)-1 (Singh et al., 2009b), which is expressed on murine
plasmacytoid DC, CD8+ and CD8- splenic DC, DC in the small intestines, the sub-capsular and intra-
follicular sinuses of T cell areas in lymph nodes, and on DC and macrophages in the dermis of skin
(Dupasquier et al., 2006; Tsuiji et al., 2002; Denda-Nagai et al., 2010; Segura et al., 2010).
Murine MGL1 is one of two homologues (MGL1 and MGL2) of human MGL (huMGL), which has
been shown to interact with tumor cells through glycans exposed on MUC1 as well as with various
pathogens (van Vliet et al., 2008). However, MGL1 and MGL2 bind different glycan structures:
while MGL1 binds LeX and Lea glycans, MGL2 binds N-acetylgalactosamine (GalNAc) and galactose
glycan structures (Singh et al., 2009b). The YENF motif in the cytoplasmic tail of huMGL is essential
for uptake of soluble antigens, which are subsequently presented to CD4+ T cells (van Vliet et al.,
2007). Murine MGL1 contains a similar motif (YENL) in its cytoplasmic tail, which likely plays a similar
and important role in antigen uptake (Yuita et al., 2005). Glycan binding to the CLRs DC-SIGN, Dec-
tin-1 and Dectin-2 has been demonstrated to trigger the signaling capacity of these receptors, mod-
ulating DC-mediated T helper cell (Th) differentiation and cytokine production by DCs
(Geijtenbeek and Gringhuis, 2009). This illustrates that glycan epitopes may not only improve anti-
gen presentation, but may also affect Th differentiation and shape specific adaptive immune
responses. This is underlined by the observation that DC-SIGN signaling induced upon sensing of
specific mannose or fucose structures on pathogens differentially directed Th differentiation
(Gringhuis et al., 2014).
Here, we demonstrate that conjugation of the LeX carbohydrate to the model antigen OVA alters
its routing from a MR- and TAP1-dependent cross-presentation pathway into a TAP1- and Cathep-
sin-S-independent pathway, devoid of any TLR-signaling dependence, which simultaneously
enhanced CD8+ T cell priming and Th1 skewing of CD4+ T cells. Cross-presentation was associated
with prolonged intracellular storage of antigen in Rab11+LAMP1+ vesicles. Our results illustrate that
small changes in the glycosylation profile of protein antigens can have a great impact on antigen
routing within DCs, affecting cross-presentation and Th cell differentiation.
Results
Identification of glycans on native and glycan-modified OVA, and the
consequences for CLR-specific binding and cross-presentation
The well-known model antigen OVA carries one N-glycosylation site at N293 and, although the vari-
ety of OVA glycans have been previously described, their relative abundance has never been charac-
terized in detail. We determined the glycan profile of OVA by normal-phase HPLC coupled with
electrospray ionization mass spectrometry with an intercalated fluorescence detector. We found that
the majority of glycan species on OVA corresponded to the complex-type (54.9%), while mannose-
rich glycans (mainly Man5 and Man6, potential ligands of the MR (Taylor and Drickamer, 1993))
represented only 23% of all glycoforms (Figure 1A). The remaining glycoforms were of the hybrid
(16.2%) and oligomannose (Man3, 3%) type. The presence of mannose rich glycans on OVA correlate
with the earlier reports that in particular MR interacted with OVA (Burgdorf et al., 2006) and medi-
ated the TLR dependent and TAP-1 dependent cross-presentation of OVA (Burgdorf et al., 2008).
We reasoned that the conjugation of additional glycans to OVA would alter its CLR-dependent
effects. To do this, we conjugated the tri-saccharide glycan structure LeX (Galb1–4(Fuca1–3)GlcNAc)
to the free cysteins of OVA using standard thiol-maleimide chemistry via the bifunctional crosslinker
MPBH. LeX is a well characterized carbohydrate ligand of the C-type lectin MGL1 (Hawiger et al.,
2001; Singh et al., 2009b). Using mass spectrometry (MALDI-TOF/TOF), we confirmed that OVA-
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LeX increases to 1.2 KDa in mass, indicating that at least 40% of the total OVA-LeX preparation con-
tained the LeX (Figure 1—figure supplement 1). This increase corresponded to the addition of two
LeX molecules per OVA molecule.
Furthermore, using anti-LeX antibodies the presence of LeX was detected on OVA-LeX, whereas
absent on native glycosylated OVA, indicating that the glycan was successfully conjugated to OVA
(Figure 1B). While native OVA interacted with the MR (MR-Fc, Figure 1B) and as earlier described
Figure 1. Generation of OVA-neo-glycoconjugates with LeX that confers binding of OVA to MGL1. (A) A glycan profile of OVA was generated using a
multidimensional normal phase nano-HPLC coupled with an electrospray ionization interface mass spectrometer with an intercalated nanofluorescence
detector. The different glycan species, indicated by numbers, are shown on the right; their relative proportion is represented in a pie chart. (B) ELISA
showing functional modification of OVA with LeX glycans, as detected with anti-LeX antibodies and resulting in binding of MGL1-Fc. Unconjugated OVA
does not carry any ligands for MGL1. Modification of OVA with LeX did not alter the ability to bind to MR as illustrated by equal binding kinetics of MR-
Fc to native OVA and OVA-LeX. OVA and OVA-LeX preparations contain similar amounts of OVA as detected with anti-OVA antibodies.
DOI: 10.7554/eLife.11765.003
The following figure supplement is available for figure 1:
Figure supplement 1. The MALDI-TOF/TOF mass spectrum of OVA-LeX (Red) shows an increase of 1,2 KDa compared to unconjugated OVA (Blue),
corresponding to addition of two LeX molecules per OVA molecule.
DOI: 10.7554/eLife.11765.004
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Figure 2. Immunization with OVA-LeX induces increased CD8+ T cell responses in vivo. (A) Expression of murine
MGL on BM-DCs and CD11c+ spDCs was analyzed by flow cytometry. (B) MGL1 mRNA expression by BM-DC and
splenic DC from WT and MGL1 KO mice was determined using qRT-PCR. GAPDH was used as a reference gene
and the results are representative of three independent experiments. C57BL/6 mice were immunized s.c. with
either OVA-LeX or native OVA mixed with anti-CD40 using a prime-boost protocol. Spleens were analyzed by flow
cytometry to determine the frequency of (C) H2-Kb/SIINFEKL-tetramer-binding CD8+ T cells and IFN-g or TNF
production by activated CD8+ T cells was determined by intracellular staining after OVA-specific re-stimulation ex
vivo. Dots represent individual mice (n=4–5 mice/group; **p<0.01). Bars indicate median of each group. Graphs
shown are representative of two independent experiments. (D) C57BL/6 and MGL1 KO mice were prime-boosted
with either OVA-LeX or native OVA mixed with anti-CD40. Frequencies of IFN-g and TNF-double-producing CD8+
T cells were determined by intracellular staining after OVA-specific re-stimulation of splenocytes ex vivo. Dots
represent individual mice (n=4–5 mice/group; *p<0.05 ***p<0.001). Bars indicate median of each group. Data are
representative of 2 independent experiments.
Figure 2 continued on next page
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(Burgdorf et al., 2007), the conjugation of LeX to OVA conferred high-avidity binding to MGL1 as
revealed using the soluble recombinant form of MGL1 (MGL1-Fc, Figure 1B). Moreover, the addi-
tion of LeX to OVA did not result in increased binding to the MR binding, indicating that LeX selec-
tively binds MGL1. Similar binding with an anti-OVA antibody was determined, which indicates that
similar protein concentrations in the preparations of OVA and OVA-LeX used in our study are pres-
ent (Figure 1B, right panel). In conclusion, through glycan profiling we identified 23% mannose-rich
glycans on native OVA that may facilitate MR binding. Addition of the glycan LeX, next to these man-
nose glycans, on cysteine residues (two LeX moieties per molecule), conveyed MGL1 specificity to
OVA.
OVA-LeXbinds MGL1 and augments priming of OVA-specific CD8+ T
cells in- vivo
We explored the potency of OVA-LeX to enhance T cell priming in vivo. Since DC are crucial for
priming of naive T cells, we first established the presence of MGL on both splenic and bone marrow-
derived DC (spDCs and BM-DCs) of C57BL/6 mice by staining with the anti-MGL antibody ER-MP23
(Figure 2A). Since the ER-MP23 antibody does not discriminate between the two murine MGL
homologues MGL1 and MGL2, MGL1 expression in wild type (WT) CD11c+ DCs was confirmed using
qRT-PCR (Figure 2B). Immunization of mice with OVA-LeX mixed with agonistic anti-CD40 antibod-
ies resulted in the enhanced priming of OVA-specific CD8+ T cells as revealed from both higher
numbers of OVA/H-2Kb tetramer binding CD8+ T cells and OVA-specific IFN-g and TNF-producing
CD8+ T cells than obtained with native OVA (Figure 2C, Figure 2—figure supplement 1). Using
MGL1KO mice, that lack MGL1 expression on DC (Figure 2B), we ascertained that MGL1 is the
prime lectin involved in boosting the generation of antigen-specific effector T cells as upon immuni-
zation of these mice with LeX-conjugated OVA no enhanced frequencies of OVA-specific IFN-g and
TNFa-double-producing T cells were detected (Figure 2D, Figure 2—figure supplement 1). In fact,
the OVA-LeX immunized MGL1 KO mice displayed comparable numbers of effector T cells as WT
mice immunized with native OVA. Together, these data show that the conjugation of two LeX gly-
cans on OVA re-directs OVA to the CLR MGL1 and thereby enhances CD8+ T cell priming in vivo.
OVA-LeX induces Th1 skewing of naive CD4+ T cells
Since we observed that LeX-modified OVA increased priming of antigen-specific CD8+ T cells we
examined whether this also enhanced antigen-presentation to CD4+ T cells. Both OVA-LeX-loaded
and native OVA-loaded spDCs induced CD4+ OT-II T cell proliferation to a similar extent
(Figure 3A), illustrating that the altered antigen uptake mediated by LeX did not affect loading on
MHC class II molecules. Similar results were obtained using BM-DCs (Figure 3A). Although we did
not observe any differential effect of LeX on CD4+ T cell expansion, neoglycosylation of antigens
could induce signaling via CLRs and herewith potentially influence Th cell differentiation
(Gringhuis et al., 2014). We therefore investigated whether OVA-LeX affected the differentiation of
naive CD4+ T cells. Hereto BM-DCs and spDCs of C57BL/6 mice were pulsed with OVA-LeX and sub-
sequently co-cultured with naive CD4+CD62Lhi OT-II cells. Co-cultures containing OVA-LeX loaded
BM-DCs or spDCs contained significantly more IFN-g-producing T cells than those containing OVA-
loaded DCs (Figure 3B). Neither induction of IL-4- nor IL-17A-producing CD4+ T cells was observed
(Figure 3B, upper and middle panel and data not shown). In addition, induction of Foxp3+ T cells
was not detected (data not shown). To exclude that the Th1 skewing by OVA-LeX loaded DCs was
Figure 2 continued
DOI: 10.7554/eLife.11765.005
The following figure supplements are available for figure 2:
Figure supplement 1. Representative flow cytometry plots of (A) IFN-g and (B) TNF- producing CD8+ T cells in
spleens of C57BL/6 mice that were immunized with either OVA-LeX or native OVA mixed with anti-CD40 using a
prime-boost protocol; numbers above the gates designate the percentage of IFN-g+ or TNF+ CD8+ T cells.
DOI: 10.7554/eLife.11765.006
Figure supplement 2. C57BL/6 and MGL1 KO mice were prime-boosted with either OVA-LeX or native OVA
mixed with anti-CD40.
DOI: 10.7554/eLife.11765.007
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Figure 3. Modification of OVA with LeX structures skews naive CD4+ T cells towards the Th1-effector lineage. (A) Pulsing of CD11c+ spDCs or BM-DCs
with OVA-LeX results in equal OT-II proliferation as native OVA. Expansion of OVA-specific T cells was determined using 3H-thymidine incorporation.
Data are shown as mean ± SD of triplicate cultures, representative of three independent experiments. (B) Flow cytometric analysis of OT-II or DO11.10
T cells differentiated by OVA-LeX or OVA-loaded spDCs or BM-DCs. Cells were gated on CD4+ T cells. Numbers in dot plots indicate the percentage
of IFN-g+ or IL-4+ of CD4+ T cells. Dot plots are representative of five independent experiments. (C) C57BL/6 mice were immunized s.c. with either
OVA-LeX or native OVA mixed with anti-CD40 using a prime-boost protocol and the frequency of IFN-g-producing activated CD4+ T cells in spleen was
determined by intracellular staining after OVA-specific re-stimulation ex vivo. Dots represent individual mice, bars indicate median of each group (n=5
mice/group, **p<0.01). Graphs shown are representative of two independent experiments.
DOI: 10.7554/eLife.11765.008
The following figure supplements are available for figure 3:
Figure supplement 1. No enhanced expansion of OT-II T cells when co-cultured for six days with OVA-LeX pulse-loaded DCs.
Figure 3 continued on next page
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attributed to the more Th1 prone status of C57BL/6 (Gervais et al., 1984), we also performed the
Th-differentiation assay with cells derived from Th2 prone BALB/c mice (Hsieh et al., 1995). We
observed that naive OVA-specific CD4+ T cells from DO11.10 Tg mice that were stimulated with
OVA-loaded BM-DCs differentiated into IL-4 secreting T cells (Figure 3B, lower panels). However,
the generation of IL-4-producing T cells was not influenced by loading DCs with OVA-LeX as these
cultures contained comparable percentages of IL-4-producing DO11.10 T cells. Using these Th2-
prone T cells, OVA-LeX-pulsed DCs still induced considerably more IFN-g-producing CD4+ T cells
than native OVA-pulsed DCs (Figure 3B, lower panel). Since this assay takes three days longer than
the antigen-presentation assay, it is possible that the higher frequency of IFN-g-producing CD4+ T
cells is due to increased division of OVA-specific CD4+ T cells. However we found that the amount
of proliferation of OVA-specific CD4+ T cells induced by stimulation with OVA-LeX-loaded DCs after
6 days is similar to that induced by OVA-loaded DCs (Figure 3—figure supplement 1). The aug-
mented induction of CD4+ Th1 cells was also observed in vivo as revealed from the higher frequen-
cies of IFN-g-producing OVA-specific CD4+ T cells in the spleens of OVA-LeX immunized mice than
in mice immunized with native OVA (Figure 3C, Figure 3—figure supplement 2). These data indi-
cate that the increased numbers of Th1 cells induced by OVA-LeX-loaded DC are not due to
increased proliferation of OT-II cells, but probably due to MGL1-mediated signaling.
MGL1 mediates cross-presentation of OVA-LeX independently of TLR
signaling
Since we observed a great enhancement of antigen-specific CD8+ T cell priming in vivo when immu-
nizing with OVA-LeX to target MGL1, we wanted to reveal the mechanism that regulates this aug-
mented cross-priming. The internalization of OVA by BM-DC was significantly increased when OVA
was modified with LeX (Figure 4A—figure supplement 1). To investigate whether the addition of
LeX glycans affected the efficiency of cross-presentation of OVA by DC, we loaded murine BM-DC
or spDC with OVA-LeX and measured their potency to present OVA-derived peptides in MHC class I
by measuring the proliferation of OVA-specific OT-I T cells. Strikingly, both BM-DCs as well as spDCs
induced substantially more proliferation of OT-I T cells when they were pulsed with OVA-LeX com-
pared to native OVA (Figure 4B—figure supplement 2). Even at low concentrations of antigen (i.e.
7.5 mg/ml), the proliferating OT-I T cells were doubled (26.7% to 51.7%) using OVA-LeX compared
to using OVA (Figure 4B), indicating that the modification of OVA with LeX greatly affected the
cross-presentation of OVA. Moreover, detection of SIINFEKL/H-2Kb complexes on the cell mem-
brane of OVA-LeX-loaded DCs by staining with the 25.1D1 antibody confirmed enhanced antigen
loading on MHC-I molecules and transportation to the cell-surface of internalized OVA-LeX com-
pared to native OVA (Figure 4C + Figure supplement 3). Cross-presentation of OVA-LeX was clearly
mediated by MGL1 as demonstrated using MGL1 KO BM-DCs or steady-state spDCs (Figure 4D).
Cross-presentation of OVA via the MR was shown previously to be dependent on TLR signaling
and the presence of high amounts of antigen ([Burgdorf et al., 2006; Burgdorf et al., 2008;
Blander and Medzhitov, 2006] and Figure 4—figure supplement 4, left panel). The observed dif-
ferences in cross-presentation between OVA and OVA-LeX were not due to any potential contamina-
tion with the TLR4 ligand LPS, as both protein preparations did not trigger IL-8 production by TLR4-
transfected HEK293 cells (Figure 4—figure supplement 5). In addition, both OVA preparations nei-
ther induced maturation of BM-DCs nor altered their cytokine production (data not shown). To
exclude any potential role of TLR signaling on the MGL1-mediated cross-presentation of OVA-
LeX, we made use of BM-DCs from mice that lack both MyD88 and TRIF (i.e. MyD88/TRIF DKO).
However, MyD88/TRIF DKO BM-DCs still induced more OT-I proliferation when targeted with OVA-
LeX than with OVA (Figure 4E) and only a slight reduction of cross-presentation was observed com-
pared to that induced by WT BM-DCs, suggesting a minor role for MyD88- or TRIF-signaling in
MGL1-induced cross-presentation. In line with previous findings, neither exogenous loading of
Figure 3 continued
DOI: 10.7554/eLife.11765.009
Figure supplement 2. C57BL/6 mice were immunized s.c. with either OVA-LeX or native OVA mixed with anti-CD40 using a prime-boost protocol and
the frequency of IFN-g-producing activated CD4+ T cells in spleen was determined by intracellular staining after OVA-specific re-stimulation ex vivo.
DOI: 10.7554/eLife.11765.010
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Figure 4. MGL1 mediates cross-presentation of OVA-LeX independently of TLR signaling. (A) Uptake of fluorescent-labeled OVA-LeX or native OVA (30
mg/ml) by WT BM-DCs was analyzed by flow cytometry after 90 min. Graphs indicate the mean ± SD of triplicates and are representative of three
independent experiments. (B) CFSE-labeled OT-I T cells were incubated with BM-DCs pulse-loaded with indicated concentrations of OVA-LeX or OVA
for 4h. Un-loaded DC served as controls. Proliferation of OT-I T cells was analyzed after 3 days by flow cytometry. Percentages of divided OT-I cells are
indicated. (C) OVA-LeX induces more OVA257-264/H2-Kb I complexes at the cell-surface of DCs than native OVA, as shown by 25.1D1 staining 18h after
pulse loading of BM-DCs with OVA-LeX or native OVA. *p<0.05. (D) WT or MGL1 KO BM-DCs or CD11c+ spDCs are pulsed with OVA-LeX (black bars)
or native OVA and OT-I proliferation was determined on day 3 by [3H]-thymidine uptake. Data are presented as mean ± SD of triplicates, representative
of three independent experiments. ***p<0.001, ns not significant. (E) Cross-presentation of OVA-LeX is independent of MyD88 and/or TRIF signaling.
BM-DC from WT or MyD88/TRIF DKO mice were pulsed with indicated concentrations of antigen and co-cultured with OT-I T cells. DCs pulsed with
Figure 4 continued on next page
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MHC-I molecules with OVA257-264 peptides (Figure 4E) nor MHC class II presentation of OVA-LeX
and OVA was dependent on MyD88- or TRIF- signaling and resulted in comparable expansion of
OVA-specific T cells (data not shown).
Cross-presentation induced by MGL1-targeting is independent of TAP-
transport and Cathepsin-S -induced endosomal degradation
Several cross-presentation pathways have been described, one of which is dependent on the trans-
port of peptides from the cytosol into MHC-class I loading compartments via TAP-molecules
(Amigorena and Savina, 2010; Adiko et al., 2015), whereas another cross-presentation pathway
depends on endosomal degradation by the cysteine protease Cathepsin-S (Shen et al., 2004). To
study a role for TAP transporters in our model, BM-DCs of TAP1 KO and WT control mice were
pulsed with OVA-LeX followed by incubation with OT-I T cells. Surprisingly, cross-presentation
induced by OVA-LeX was not reduced by the absence of TAP as OT-I proliferation induced by OVA-
LeX-loaded TAP1 KO BM-DCs was not decreased compared to OVA-LeX-loaded WT BM-DC
(Figure 5A). In accordance with previous publications (Burgdorf et al., 2008), we showed that
the administration of OVA with LPS is cross-presented in a TAP-dependent manner (Figure 4—fig-
ure supplement 2). Furthermore, the possibility that the results are confounded by reduced levels
of MHC-class I on TAP1 KOBM-DCs were excluded as the presentation of exogenously loaded
OVA257-264 peptide is equal by both WT and TAP1 KOBM-DCs (Figure 5A). In addition, we
excluded the involvement of the Cathepsin-S pathway for cross-presentation of OVA-LeX as cross-
presentation of OVA-LeX by BM-DCs from Cathepsin-S KO mice (Cat-S KO) was not reduced com-
pared to WT BM-DCs (Figure 5B). As expected, the MHC-class II-restricted CD4+ T cell proliferation
was compromised in the Cat-S KO BM-DCs (data not shown), illustrating the involvement of Cathep-
sin-S in cleaving the invariant chain of the MHC-class II molecule (Nakagawa et al., 1999).
Modification of OVA with LeX alters the intracellular routing of OVA
As the dominant cross-presentation of LeX-modified OVA was neither dependent on TAP nor
required TLR signaling, we hypothesized that this may be due to the altered uptake and intracellular
routing of OVA in DCs. We therefore used imaging flow cytometry, a method that allows high-
throughput image analysis of cells in flow with near-confocal resolution to analyze the intracellular
routing of fluorescent labeled OVA-LeX. Co-staining with markers for early endosomal (EEA-1), late
endosomal/lysosomal (LAMP1) and recycling endosomal (Rab11) compartments illustrated a swift
co-localization of OVA-LeX with EEA1 and Rab11 as shown by high co-localization scores at 15 min
(Figure 6A, Figure 6—figure supplement 1). However, this co-localization score was strongly
decreased at 60 min. At this time-point, higher co-localization scores were detected for OVA-LeX
with LAMP1 and Rab11 (Figure 6B, Figure 6—figure supplement 2). We then further dissected the
intracellular pathway of OVA-LeX using confocal laser scan microscopy (CLSM) and compared it to
Figure 4 continued
the nominal epitope SIINFEKL served as controls (right panel). Proliferation was determined by [3H]-thymidine uptake. Data are representative of two
experiments and indicated as mean ± SD of triplicates.
DOI: 10.7554/eLife.11765.011
The following figure supplements are available for figure 4:
Figure supplement 1. Uptake of fluorescent-labeled OVA-LeX or native OVA (30 mg/ml) by WT BM-DCs was analyzed by flow cytometry after 90 min
(upper panel).
DOI: 10.7554/eLife.11765.012
Figure supplement 2. Enhanced cross-presentation of OVA-LeX by DCs as measured by 3H-Thymidine incorporation.
DOI: 10.7554/eLife.11765.013
Figure supplement 3. Representative flow cytometry plots of 25.1D1 staining of BM-DCs 18h after pulse loading with OVA-LeX or native OVA (750 ug/
ml).
DOI: 10.7554/eLife.11765.014
Figure supplement 4. Cross-presentation of OVA requires TLR4 triggering and is TAP-dependent.
DOI: 10.7554/eLife.11765.015
Figure supplement 5. OVA-LeX formulations are free of endotoxins.
DOI: 10.7554/eLife.11765.016
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the intracellular routing of native OVA. We confirmed that native OVA, which internalized via MR,
was routed to EEA1+Rab11+ compartments within 2h (Figure 6C, upper-left panel and
[Burgdorf et al., 2008]). However, the neoglycosylation with LeX altered the intracellular routing of
OVA, showing its presence predominantly within LAMP1+Rab11+ compartments (Figure 6C, upper-
right panel). Moreover, OVA-LeX internalized by BM-DC from MGL1 KO mice was routed to EEA1+-
Rab11+ compartments and did not end up in LAMP1+Rab11+ compartments, similar to OVA in WT
BM-DC (Figure 6C, lower panels + Figure 6—figure supplement 3). Together, these data suggest
that upon internalization, OVA-LeX is rapidly shuttled to Rab11+EEA1+ compartments from where it
moves to Rab11+LAMP1+ compartments, where it persists for longer periods (i.e. >24h). Thus, these
results indicate that internalization via MGL1 allows the antigen to enter the endosomal/lysosomal
pathway.
The development of early endosome into late endosome/lysosome coincides with a decreasing
pH gradient. The pH at which MGL1 dissociates from its ligand is indicative of the compartment in
which the antigen becomes available for degradation and loading on MHC-molecules. We therefore
analyzed MGL1-binding to its ligand LeX at different pH that resembled the pH of the intracellular
compartments. MGL1 starts dissociating from LeX already at pH 6.5 (Figure 6D). This indicates that
OVA-LeX becomes available for degradation in the early and late endosomal compartments, com-
partments both associated with cross-presentation.
The sustained presence of OVA-LeX in Rab11+LAMP1+ compartments (Figure 6B+C) prompted
us to investigate whether these compartments facilitate prolonged cross-presentation, as shown by
van Montfoort et al. for OVA-immune complexes (van Montfoort et al., 2009). Indeed, even two
days after antigen pulse, OVA-LeX-loaded DC induced strong expansion of OT-I T cells, suggesting
that OVA-LeX-loaded DC have prolonged cross-presentation capacity (Figure 7A). At the highest
antigen concentration used (i.e. 30 mg/ml), the percentage of proliferated OT-I T cells was only
slightly reduced 48 h after pulse compared to that induced by DCs that were pulsed with OVA-LeX
for 4 h (Figure 7A). Expansion of OT-I T cells driven by 48 h pulse loaded DCs was even detectable
at low antigen concentrations (3.75 mg/ml). OT-II proliferation induced by DCs pulsed with OVA-LeX
for 48h was also still detectable although less pronounced than the OT-I induced proliferation
(Figure 7B), suggesting that the prolonged storage of antigen in these intracellular compartments
predominantly favored cross-presentation.
Figure 5. LeX-modified antigen is cross-presented in a TAP- and Cathepsin-S-independent fashion. To examine whether cross-presentation of OVA-LeX
involves TAP or Cathepsin-S (A) TAP1 KO and (B) Cat-S KO BM-DCs and WT BM-DCs were pulsed with OVA-LeX or native OVA and co-cultured with
OT-I T cells for 3 days. DCs exogenously loaded with SIINFEKL for 3h served as control. Proliferation was determined by [3H]-Thymidine uptake and
data are presented as mean ± SD of triplicates (representative of three experiments).
DOI: 10.7554/eLife.11765.017
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Figure 6. OVA-LeX is routed to Rab11+LAMP1+ compartments where it is stored for presentation in MHC class I.
(A, B) WT BM-DCs were pulsed with AlexaFluor 674-OVA-LeX (30 mg/ml) and chased at the indicated time-points
to assess triple co-localization scores of OVA-LeX with (A) EEA-1 and Rab11 or (B) LAMP1 and Rab11 using
imaging flow cytometry. (C) WT (upper panels) and MGL1 KO (lower panels) BM-DCs were incubated with Dylight-
633-OVA-LeX or native OVA (30 mg/ml) and 2h later co-localization of OVA antigen (Red) with early endosomal
(EEA-1, Green) or endosomal/lysosomal (LAMP1, Green) and recycling endosomal (Rab11, Blue) compartments
was analyzed using CSLM. From a z-stack, histograms were created for a selected area (indicated by a line, upper
part of each panel) using the Leica confocal software. Histograms were created from each fluorochrome and
overlays were made by the program. Arrows indicate co-localization of antigen (Red) with EEA1&Rab11 or
LAMP1&Rab11. (D) MGL1-Fc binding to LeX-PAA was determined at indicated pH by ELISA.
Figure 6 continued on next page
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Taken together, these data suggest that antigen internalized by MGL1 is routed from RAb11+-
EEA1+ compartments towards Rab11+LAMP1+ compartments, which seem to associate with the
extended antigen-processing and cross-presentation.
Discussion
We here demonstrate that the glycosylation-profile of antigens has a major influence on antigen
uptake and intracellular compartmentalization, thereby affecting both antigen presentation and the
type and strength of the induced immune response. Modification of the model-antigen OVA with
LeX glycans directs OVA towards MGL1, skewing naive CD4+ T cell differentiation towards IFNg-pro-
ducing Th1 cells. Moreover, targeting OVA to MGL1 through the conjugation of LeX, substantially
enhanced cross-presentation as revealed by the increased frequency of OVA-specific CD8+ effector
T cells in vitro and in vivo. Importantly, MGL1-dependent cross-presentation occurred at low antigen
dose and independently of TLR-signaling. Moreover, this cross-presentation pathway did not involve
TAP-transporters and Cathepsin-S. MGL1 targeting involved antigen routing to a Rab11+LAMP1+
compartment in which antigen was present for prolonged periods.
Previous studies on CLR-mediated antigen uptake and cross-presentation, in particular by the
MR, demonstrated a clear requirement for a TLR ligand (Kovacsovics-Bankowski and Rock, 1995;
Burgdorf et al., 2008; Sancho et al., 2008; Segura et al., 2009). A common denominator in some
of these studies is that the use of antibody–antigen conjugates could potentially induce a different
signal than the natural ligand, due to binding to different part of the receptor or through co-engage-
ment of Fc-receptors. The fact that the addition of LeX glycans to OVA obviates the need for TLR
signals for the induction of cross-presentation and Th1 priming in vitro, may indicate that MGL1 sig-
naling is involved in these processes. Some CLR, like DC-SIGN, Clec9A and Dectin-1 are known to
induce signaling after triggering by their natural ligands (Geijtenbeek and Gringhuis, 2009;
Sancho et al., 2009). Till now, no signaling pathway has been described for MGL1. Triggering of
huMGL resulted in ERK1/2 and NF-kB activation, and results in elevated levels of IL-10 and TNF
(Li et al., 2012; van Vliet et al., 2013). In our studies, the uptake of LeX-modified OVA through
MGL1 was not associated with any DC maturation or altered cytokine production by DCs. The fact
that OVA-LeX induced an enhanced frequency of Th1 cells in vitro and of antigen-specific effector T
cells in vivo when combined with agonistic anti-CD40 Abs illustrates that a yet to be determined cos-
timulatory signal is essential for the induction of effector CD8+ and CD4+ T cells. This powerful func-
tion of MGL1 to establish antigen-specific immunity, stands opposite to its recently demonstrated
anti-inflammatory function, which include induction of IL-10 production and altered adhesive func-
tion by APC (Saba et al., 2009; Westcott et al., 2009).
Various models for cross-presentation of antigens have been contemplated. The ’cytosolic
pathway’ of cross-presentation allows receptor-mediated endocytosis or phagocytosis and antigen
translocation into the cytosol, where they are degraded into antigenic peptides by the proteasome
and transported into the lumen of the endoplasmic reticulum (ER) (Kovacsovics-Bankowski and
Rock, 1995; Shen et al., 2004) or ER/phagosomal fusion compartments (Guermonprez et al.,
Figure 6 continued
DOI: 10.7554/eLife.11765.018
The following figure supplements are available for figure 6:
Figure supplement 1. Examples of WT BM-DCs pulsed with AlexaFluor 674-OVA-LeX displaying high co-
localization of OVA-LeX with EEA-1 and Rab11 as measured by imaging flow cytometry.
DOI: 10.7554/eLife.11765.019
Figure supplement 2. Examples of WT BM-DCs pulsed with AlexaFluor 674-OVA-LeX displaying high co-
localization of OVA-LeX with LAMP1 and Rab11 as measured by imaging flow cytometry.
DOI: 10.7554/eLife.11765.020
Figure supplement 3. WT (upper panels) and MGL1 KO (lower panels) BM-DCs were incubated with Dylight-633-
OVA-LeX or native OVA (30 mg/ml) and 0.5 h and 2 h later co-localization of OVA antigen (Red) with early
endosomal (EEA-1, Green) or endosomal/lysosomal (LAMP1, Green) and recycling endosomal (Rab11, Blue)
compartments was analyzed using CSLM.
DOI: 10.7554/eLife.11765.021
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2003; Houde et al., 2003) by TAP-transporters. A variation to the cytosolic pathway was described
in which soluble OVA is taken up via the MR and is supplied to stable early endosomal compart-
ments (Burgdorf et al., 2007). In these compartments, the MHC class I machinery as well as TAP-
transporters are selectively recruited, facilitating direct loading of antigen-derived peptides onto
MHC class I molecules without trafficking to the ER. The ’vacuolar pathway’ allows antigens to be
degraded into peptides in early endosomal compartments by endosomal proteases like Cathepsin-
S, to be loaded on MHC class I molecules in the same compartment, thus is TAP-independent
(Shen et al., 2004). The current described models for cross-presentation depend on peptide-trans-
port by TAP from the cytosol to either ER or ER/phagosomal fusion compartments or on endosomal
degradation of antigens via Cathepsin-S (reviewed in [Amigorena and Savina, 2010; Burgdorf and
Kurts, 2008; Mintern et al., 2015; Adiko et al., 2015]). Although we observed localization of OVA-
LeX in early endosomes, absence of either TAP molecules or Cathepsin-S did not influence the
enhanced cross-presentation of OVA-LeX. Our data indicate that the MGL1 cross-presentation
Figure 7. MGL1 targeting with OVA-LeX shows sustained antigen presentation in MHC-I. WT BM-DCs were pulsed for 4 h with titrated amounts of
OVA-LeX and washed with culture medium. DCs were then chased for 48 h in antigen-free medium. (A) BM-DCs pulsed for 4h with OVA-LeX induced
MHC-I antigen presentation as measured by CFSE-labeled OVA-specific OT-I cells (upper panel). Sustained presentation is shown after 48 h (lower
panel). (B) MHC-II antigen presentation 4h and 48h after pulse-loading with OVA-LeX, analyzed by OT-II proliferation. Data are presented as percentage
of proliferated T cells and representative of three independent experiments.
DOI: 10.7554/eLife.11765.022
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pathway is different than that of the MR and may occur via antigen storage compartments similar to
those described for FcgR-targeted antigens (van Montfoort et al., 2009). We observed prolonged
presence in Rab11+LAMP1+ compartments in the absence of a maturation stimulus or apparent DC
maturation. It is tempting to speculate that in these compartments cross-presentation of OVA is
facilitated by Rab11 as it was recently shown that Rab11 activity mediates delivery of MHC-I mole-
cules to phagosomes used for cross-presentation during infection (Nair-Gupta et al., 2014). How-
ever, recruitment of additional components involved in antigen cross-presentation by the SNARE
Sec22b40 complex cannot be excluded (Cebrian et al., 2011). The prolonged antigen cross-presen-
tation via MGL1 allows sustained cross-priming of CD8+ T cells in vivo and thus the efficacy of tumor
vaccines that target MGL1 may be higher than of conventional vaccines containing non-targeted
antigens.
In the current study, we show that already at very low concentrations, soluble protein antigens
are efficiently cross-presented upon uptake by MGL1. DCs pulsed with a low dose of OVA-LeX
(7.5 mg/ml) induced significant CD8+ T cell proliferation, whereas the same concentration of native
OVA was hardly cross-presented (Figure 4). Others have demonstrated that native OVA can only be
cross-presented when a high dose was used (0.5–1.0 mg/ml) and when accompanied with TLR-trig-
gering (Burgdorf et al., 2008; Segura et al., 2009). Although the glycan-modification was associ-
ated with increased antigen uptake and enhanced cross-presentation, it did not result in enhanced
presentation of antigen on MHC-class II indicating that increased uptake of antigen is not per se a
requirement to facilitate MHC class I and II presentation. Therefore, it is most likely that the CLR
(and thus the glycosylation of the antigen) dictates how efficiently an antigen is cross-presented.
Based on our study, MGL1 cross-presents antigen much more efficiently than the MR.
The activity of the glycosylation machinery is subjected to subtle regulation and depends on the
cell-type or activation status of the cell. Upon malignant transformation glycan profiles may change
dramatically. LeX carbohydrate structures are described to be expressed in the brain
(Lieberoth et al., 2009), and can be de novo expressed on cancer stem cells (Read et al., 2009) or
pathogens, and the glycosylation pattern of in vivo accumulating antigens, being brain tissue, tumor
tissue or pathogen structure, is crucial for directing specific CLR antigen uptake and cross-presenta-
tion (Hittelet et al., 2003; Ohana-Malka et al., 2003). Although in our studies only two LeX glycans
were conjugated to each OVA molecule, it cannot be ruled out that multivalent presentation of LeX,
such as often observed on tumors or pathogens (Bergman et al., 2004; Saeland and van, 2011),
may alter avidity-induced MGL-1 signaling and antigen presentation, and induce an anti-inflamma-
tory immune repertoire. At this stage, we do not know whether high glycan valency further enhances
or inhibits the MGL1-mediated (cross-)priming.
The fact that pulsing of DCs with OVA-LeX resulted in improved cross-priming and Th1-skewing
indicates that conjugation of these carbohydrates to tumor-antigens could be beneficial for
the induction of potent anti-tumor responses. Therefore, the use of glycans for targeting CLR for
anti-cancer immunotherapy could have several advantages. First, they mimic natural function of the
receptors, inducing ‘natural’ signaling cascades in DCs. Furthermore, they are very small molecules,
easy to use and relatively cheap to produce. Importantly, many glycans may be considered self-anti-
gens, in contrast to recombinant antibodies that are often not completely of human origin. These
properties make it possible to decorate any antigen of choice with glycans to target specific
receptors.
In conclusion, our studies indicate that the glycan composition of protein antigens is of fundamen-
tal importance in dictating the intracellular routing and Th-skewing, and should be considered as a
major determinant in the design of therapeutic vaccines against cancer and infectious diseases.
Materials and methods
Mice
C57BL/6 mice (Charles River Laboratories) were used at 8–12 weeks of age. MGL1KO mice, which
have a null mutation within the Clec10a gene, are on the C56BL/6 background and were kindly pro-
vided through the Consortium for Functional Glycomics. TAP1 KO mice have a null mutation within
the Tap1 gene. MGL1 KO, TAP1 KO, OT-I and OT-II TCR transgenic mice were bred in our animal
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facilities under specific pathogen-free conditions. All experiments were performed according to insti-
tutional, state and federal guidelines.
Antibodies and Fc-chimeric constructs
Fluorochrome-conjugated antibodies used: anti-CD11c-APC, anti-IFNg-APC, anti-TNFa-PE-cy7, anti-
IL-4-PE, anti-IL17-PE, anti-Foxp3-PE (e-Bioscience, Vienna, Austria), and anti-LAMP-1-v450 (BD-Phar-
mingen). Unconjugated mouse anti-OVA (Sigma Aldrich), mouse anti-LeX (Calbiochem), rat anti-
mMGL (ER-MP23; kind gift from Dr. P. Leenen, Erasmus MC, Rotterdam, The Netherlands), rat anti-
LAMP1 (BD-Pharmingen), rabbit anti-Rab11 (Life Technologies), goat anti-EEA1 (Santa Cruz Biotech-
nology) and rabbit anti-EEA-1 (Dianova). Secondary antibodies used: peroxidase-labeled F(ab’)2
fragment goat anti-human IgG, F(ab’)2 fragment goat anti-mouse IgG, (Jackson), peroxidase-labeled
goat anti-mouse IgM (Nordic Immunology), goat anti-rat Alexa 448, goat anti-rat Alexa 647, donkey
anti-goat Alexa 488, donkey anti-goat Alexa 647, donkey anti-rabbit Alexa 555 and donkey anti-rab-
bit Alexa 488 (Molecular Probes). MGL-1-Fc was generated as described earlier (Singh et al.,
2009b). MR-Fc was kindly provided by L. Martinez-Pomares (University of Nottingham, Nottingham,
UK).
Generation of neo-glycoconjugates
LeX (lacto-N-fucopentose III; Dextra Labs, UK) carbohydrate structures were conjugated to OVA (Cal-
biochem) as previously described (Singh et al., 2009a). In short; the bifunctional cross-linker (4-N-
maleimidophenyl) butyric acid hydrazide (MPBH; Pierce) was covalently linked to the reducing end
of the LeX and the maleimide moiety of the linker was later used for coupling the LeX to OVA. Neo-
glycoconjugates were separated from reaction by-products using PD-10 desalting columns (Pierce).
Additionally, a Dylight 549-N-hydroxysuccimide (NHS) label (Thermo Scientific) was covalently cou-
pled with OVA or OVA-LeX (Dylight-549-OVA). Free label was removed using a PD-10 column
(Pierce).
The presence of LeX and CLR binding to OVA was measured by ELISA. In brief, OVA-conjugates
were coated directly on ELISA plates (NUNC) and binding of MR-Fc, MGL1-Fc, anti-LeX and anti-
OVA antibodies to OVA was determined as described (Singh et al., 2009a; Hawiger et al., 2001).
The presence of endotoxin was measured using a LAL assay (Lonza) following manufacturer’s
protocol.
Glycan analysis
OVA was deglycosylated by incubation in 5 IU of PNGase F (Roche Applied Sciences) o/n at 37˚C.
Proteins were extracted by reverse phase chromatography using Sep-Pak Vac C18 disposable car-
tridges (Waters). Glycans were further purified by reverse phase chromatography using Superclean
ENVI-Carb cartridges disposable columns (Supelco). Glycans were lyophilized and re-dissolved in
30 ml of 7-Amino-4-methylcoumarin (160 mM, Sigma Aldrich) and 2-Picoline borane (270 mM,
Sigma Aldrich) in DMSO:acetic acid (4:1, Riedel deHae¨n). 4-AMC-labelled glycans were purified by
size exclusion chromatography using a Bio-Gel P2 (Bio-Rad) column with 50 mM ammonium formate
(Sigma Aldrich) as running buffer. 4-AMC-labelled glycans were lyophilized and analyzed by multidi-
mensional normal phase HPLC (UltiMate 3000 nanoLC, Dionex) using a Prevail Carbohydrate ES
0.075 x 200 mm column (Grace) coupled with an LCQ Deca XP with electrospray interface mass
spectrometer (Thermo Finnigan) tuned with maltoheptoase (Sigma Aldrich) labeled with 4-AMC and
with an intercalated fluorescence detector (Jasco FP-2020 Plus, Jasco) (maximum excitation 350 nm,
band width 40 nm; maximum emission 448 nm, band width 40 nm) as previously described
(Kalay et al., 2012).
Molecular weight determination
Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry measure-
ments were done using a 4800 MALDI-TOF/TOF Analyzer (Applied Biosystems). Mass spectra were
recorded in the range from to 19,000 to 155,000 m/z in the linear positive ion mode. The data were
recorded using 4000 Series Explorer Software and processed with Data Explorer Software version
4.9 (all from Applied Biosystems).
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Immunization of mice
C57BL/6 or Mgl1-/- mice were injected s.c. either with 100 mg OVA-LeX or OVA mixed with 25 mg
anti-CD40 Ab (1C10) on day 0 and day 14. Mice were sacrificed one week after boost and the
amount of antigen-specific CD8+ T cells was analyzed in the spleen by staining with H2-Kb-SIINFEKL
tetramers (Sanquin). Additionally, frequencies of OVA-specific cytokine-secreting T cells were ana-
lyzed by flow cytometry. Hereto, spleen cells were re-stimulated overnight with either 2 mg/ml SIIN-
FEKL or 200 mg/ml EKLTEWTSSNMEER OVA peptides in the presence of 5 mg/ml Brefeldin A, then
IFN-g and TNFa expression were assessed by intracellular staining using specific antibodies.
Cells
BM-DC were cultured as previously described (Singh et al., 2009a). BM of Myd88/Ticam1 DKO
(referred to as MyD88/TRIF DKO) and Ctss-/- (referred to as Cat-S KO) mice was kindly provided by
Dr. T. Sparwasser (Twincore, Hannover, Germany) and Dr. K. Rock (Massachusetts Medical School,
Worcester, MA, USA), respectively. CD11c+ spDCs were isolated as previously described
(Singh et al., 2009a). OVA-specific CD4+ and CD8+ T cells were isolated from spleen and lymph
nodes cell suspensions from OT-II and OT-I mice, respectively, using the mouse CD4 and CD8 nega-
tive isolation kit (Invitrogen, CA, USA) according to manufacturer’s protocol. T cell proliferation
assays were performed as described (Singh et al., 2009a). In short,DCs were pulsed with OVA-LeX
or OVA for 4h before incubation with OVA-specific OT-I or OT-II T cells (2:1 DC:T). [3H]-Thymidine (1
mCi/well; Amersham Biosciences) was present during the last 16h of a 72h culture. [3H]-Thymidine
incorporation was measured using a Wallac microbeta counter (Perkin-Elmer). Alternatively, OT-I or
OT-II T cells were labeled with CFSE and after 3 days dilution of CFSE was analyzed by flow cytome-
try. Differentiation of naive OT-II T cells, induced by OVA-LeX or OVA -pulsed BM-DCs or spDCs,
was measured by an in vitro Th differentiation assay described earlier (Singh et al., 2011).
cDNA synthesis and Real time PCR
mRNA was isolated by capturing poly(A+)RNA in streptavidin-coated tubes using a mRNA Capture
kit (Roche, Basel, Switzerland). cDNA was synthesized using the Reverse Transcription System kit
(Promega, WI, USA) following the manufacturer’s guidelines.
Real time PCR reactions were performed using the SYBR Green method in an ABI 7900HT
sequence detection system (Applied Biosystems).
Confocal Microscopy and imaging flow cytometry
BM-DCs were incubated with 30 mg/ml Dylight-633-OVA or OVA-LeX for 30min or 2h at 37˚C, fixed
and permeabilized for 20 min on ice, and stained with primary and secondary antibodies. Co-locali-
zation was analyzed using a confocal laser scanning microscope (Leica SP5 STED) system containing
a 63x objective lens; images were acquired in 10x magnification and processed with Leica LAS AF
software.
For imaging flow cytometry, approximately 1x106 BM-DCs were incubated with OVA-LeX for
30 min at 4˚C, washed twice in ice-cold PBS and then transferred to 37˚C. At the indicated time-
points, cells were washed twice and fixated in ice-cold 4% paraformaldehyde (PFA, Electron Micros-
copy Sciences) in PBS for 20 min. The cells were then permeabilized in 0.1% saponin (Sigma) in PBS
for 30 min at RT and subsequently blocked using PBS containing 0.1% saponin and 2% BSA for
30 min at RT. Stainings were performed at room temperature (RT) in PBS supplemented with 0.1%
saponin and 2% BSA. After staining, cells were washed twice in PBS, resuspended in PBS containing
1% BSA and 0.02% NaN3 and kept at 4˚C until analysis. The cells were acquired on an ImageStream
X100 (Amnis) imaging flow cytometer. A minimum of 15,000 cells was acquired per sample at a flow
rate ranging between 50 and 100 cells/second at 60x magnification. At least 2000 cells were
acquired from single-stained samples to allow for compensation. Analysis was performed using the
IDEAS v6.1 software (Amnis). The cells were first gated based on the Gradient RMS (brightfield) fea-
ture and then based on area vs aspect ratio intensity (both on brightfield). The first gating identified
the cells that appeared in focus, while the second excluded doublets and cells other than BM-DCs.
3-colour co-localization was calculated using the bright detail co-localization 3 feature.
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pH dependency of MGL1 binding
The pH dependency of MGL1 binding to LeX on antigens was determined by ELISA. Hereto, LeX-
PAA (Lectinity Holdings) was coated onto NUNC Maxisorp plates o/n at RT. The plates were blocked
with 1% BSA in TSM buffer (20 mM Tris-HCl; 150 mM NaCl; 2 mM CaCl2; 2 mM MgCl2). After wash-
ing, MGL1-Fc was added in TSA with different pH and were kept in this buffer throughout the assay.
Binding was detected using peroxidase-labeled F(ab’)2 fragment goat anti-human IgG.
Statistical analysis
Graphpad prism 5.0 was used for statistical analysis. The Student’s t-test and one-way ANOVA with
Bonferroni correction were used to determine statistical significance. Statistical significance was
defined as p< 0.05.
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